Endogard Plus Flavour Tablets for Dogs

Authorised

- Febantel
- Praziquantel
- Pyrantel embonate

Product identification

Medicine name:
Endogard Plus Flavour Tablets for Dogs

Active substance:
Febantel

Praziquantel

Pyrantel embonate

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Febantel

150.00 milligram(s) / 1.00 Tablet

Praziquantel
50.00 milligram(s) / 1.00 Tablet

Pyrantel embonate
144.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP52AC55

Legal status of supply:
Veterinary medicinal product not subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
United Kingdom (Northern Ireland)

Package description:
Nature of container: Print and perforated Alu-Alu blister: 300 tablets (30 blisters with 10 tablets), in a box.
Nature of container: Print and perforated Alu-Alu blister: 100 tablets (10 blisters with 10 tablets), in a box.
Nature of container: Print and perforated Alu-Alu blister: 50 tablets (5 blisters with 10 tablets), in a box.
Nature of container: Print and perforated Alu-Alu blister: 30 tablets (3 blisters with 10 tablets), in a box.
Nature of container: Print and perforated Alu-Alu blister: 10 tablets (1 blister with 10 tablets), in a box.
Nature of container: Print and perforated Alu-Alu blister: 4 tablets (2 blisters with 2 tablets), in a box.
Nature of container: Print and perforated Alu-Alu blister: 2 tablets (1 blister with 2 tablets), in a box.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:
2/06/2011

Manufacturing sites for batch release:
KRKA tovarna zdravil d.d. Novo mesto
Krka-Farma d.o.o.
Virbac

Responsible authority:
The Veterinary Medicines Directorate

Authorisation number:
Vm 01656/4017

Date of authorisation status change:
1/12/2024

Reference member state:
Ireland

Procedure number:
IE/V/0539/001

Concerned member states:
Austria Belgium Czechia Denmark Estonia Germany Greece Hungary Italy Latvia Lithuania Netherlands Poland Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics